NRX Pharmaceuticals Faces Delisting Threat, Files 8-K

TL;DR

**NRXP is facing delisting, expect major volatility and liquidity issues.**

AI Summary

NRX Pharmaceuticals, Inc. filed an 8-K on January 23, 2024, reporting an event on January 16, 2024, related to a Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard. This indicates the company is facing potential delisting from a stock exchange, which could significantly reduce liquidity and investor confidence. For current or prospective shareholders, this matters because it signals serious operational or financial issues that could lead to a substantial drop in stock value and make it harder to sell shares.

Why It Matters

This filing signals that NRX Pharmaceuticals is in danger of being delisted from a stock exchange, which typically leads to a significant decrease in stock price and makes shares much harder to trade.

Risk Assessment

Risk Level: high — A notice of delisting indicates severe non-compliance with exchange rules, posing a substantial risk to the company's stock value and tradability.

Analyst Insight

A smart investor would carefully review the specific reasons for the delisting notice (which are not detailed in this filing but implied by the item) and consider the high risk of further stock depreciation and reduced liquidity before making any investment decisions. Existing shareholders might consider exiting their position.

Key Players & Entities

• NRX Pharmaceuticals, Inc. (company) — the registrant filing the 8-K
• 001-38302 (other) — Commission File Number
• 82-2844431 (other) — I.R.S. Employer Identification No.
• Delaware (other) — State of incorporation
• 1201 Orange Street, Suite 600 Wilmington, Delaware 19801 (other) — Address of principal executive offices
• 484-254-6134 (other) — Registrant's telephone number

Forward-Looking Statements

• NRX Pharmaceuticals' stock price will experience significant downward pressure. (NRX Pharmaceuticals, Inc.) — high confidence, target: 2024-03-31
• The company will likely issue further communications regarding its plan to regain compliance or appeal the delisting notice. (NRX Pharmaceuticals, Inc.) — medium confidence, target: 2024-04-30

FAQ

Key Financial Figures

• $0.001 — h registered Common Stock, par value $0.001 per share NRXP The Nasdaq Stock Mar

Filing Documents

• tm243930d1_8k.htm (8-K) — 34KB
• tm243930d1_ex99-1.htm (EX-99.1) — 8KB
• 0001104659-24-005888.txt ( ) — 261KB
• nrxp-20240116.xsd (EX-101.SCH) — 3KB
• nrxp-20240116_def.xml (EX-101.DEF) — 26KB
• nrxp-20240116_lab.xml (EX-101.LAB) — 36KB
• nrxp-20240116_pre.xml (EX-101.PRE) — 25KB
• tm243930d1_8k_htm.xml (XML) — 5KB

01. Notice

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On October 17, 2023, NRx Pharmaceuticals, Inc. (the "Company") received formal notice from the Listing Qualifications Staff (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") indicating that, based upon the Company's non-compliance with the minimum bid price requirement for continued listing on The Nasdaq Global Market, as set forth in Nasdaq Listing Rule 5450(a)(1) (the "Rule"), the Company's securities were subject to delisting unless the Company timely requested a hearing before the Nasdaq Hearings Panel (the "Panel"). The Company timely requested a hearing before the Panel, which hearing was held on January 4, 2024. On January 16, 2024, the Panel granted the Company's request for an exception to the Nasdaq listing rules until April 16, 2024, to demonstrate compliance with the Rule. Such exception is subject to the following conditions: 1. The Company filing all necessary documentation required to transfer its listing from the Nasdaq Global Market to the Nasdaq Capital Market on or before January 19, 2024; and 2. The Company demonstrating compliance with Listing Rule 5550(a)(2) on or before April 16, 2024. We are diligently working to evidence compliance with the Rule; however, there can be no assurance that the Panel will determine to continue the Company's listing or that the Company will be able to evidence compliance with the applicable listing criteria within the time period of any extension that may be granted by the Panel. Cautionary Note Regarding

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995, which may include, but are not limited to, statements regarding our financial outlook, product development, business prospects, and market and industry trends and conditions, as well as the Company's strategies, plans, objectives, and goals. These forward-looking statements are based on current beliefs, expectations, estimates, forecasts, and projections of, as well as assumptions made by, and information currently available to, the Company's management. Actual results could differ materially from those contemplated by the forward-looking statements. Important factors that could cause actual results to differ materially from these forward-looking statements include, but are not limited to: inability of the Company to achieve any of the potential developments identified above; the timing for achieving the potential developments identified above; there is no assurance as to how the potential developments will impact the Company's stock price; and other factors, including risks and uncertainties with respect to the Company, set forth in the Company's filings with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K, as may be supplemented or amended by the Company's Quarterly Reports on Form 10-Q. Given these risks, uncertainties and factors, you are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by these cautionary statements. The Company assumes no obligation to revise any forward-looking statement, whether as a result of new information, future events or otherwise. Accordingly, you should not place reliance on any forward-looking statement, and all forward-looking statements are herein qualified by reference to the cautionary statements set forth above.

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. On January 17, 2024, the Company issued a press release announcing the Panel's decision. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference. The information set forth in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. The information set forth in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release, dated January 17, 2024 104 Cover Page Interactive Data File (formatted as Inline XBRL) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NRX PHARMACEUTICALS, INC. Date: January 23, 2024 By: /s/ Stephen Willard Name: Stephen Willard Title: Acting General Counsel

View Full Filing

View this 8-K filing on SEC EDGAR